EvolveImmune develops novel cancer immunotherapies using its proprietary EVOLVE platform to create trispecific T cell engagers with integrated CD2 costimulation. This approach is designed to overcome resistance mechanisms seen with existing immunotherapies. The company is advancing its lead candidate, EVOLVE104, into clinical trials for solid tumors.
Funding
$103.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often fail to provide durable responses due to CD8 T cell exhaustion within the tumor microenvironment. This exhaustion limits the ability of immune cells to effectively target and eliminate cancer cells, leading to disease progression and poor patient outcomes.
Solution
EvolveImmune Therapeutics is developing precision cancer medicines designed to overcome CD8 T cell exhaustion and enhance anti-tumor immunity. Their therapeutic approach focuses on selectively regulating key pathways within the tumor microenvironment to reinvigorate exhausted T cells. By targeting these mechanisms, EvolveImmune aims to drive effective and durable anti-cancer responses, leading to improved long-term outcomes for cancer patients. The company's ambition is to transform the lives of cancer patients by developing a new class of precision cancer medicines.
Target Audience
The primary target audience includes cancer patients who are not responding well to existing therapies, as well as oncologists and researchers seeking more effective and durable treatment options.
Features
- Focuses on validated pathways essential for overcoming CD8 T cell exhaustion.
- Aims to selectively regulate mechanisms within the tumor microenvironment.
- Designed to drive effective, durable anti-cancer immunity.